Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Corcept Therapeutics (CORT) FCF Margin (2016 - 2025)

Corcept Therapeutics' FCF Margin history spans 10 years, with the latest figure at 19.0% for Q4 2025.

  • For Q4 2025, FCF Margin fell 1396.0% year-over-year to 19.0%; the TTM value through Dec 2025 reached 18.62%, down 1043.0%, while the annual FY2025 figure was 18.62%, 1043.0% down from the prior year.
  • FCF Margin for Q4 2025 was 19.0% at Corcept Therapeutics, down from 26.24% in the prior quarter.
  • Across five years, FCF Margin topped out at 50.5% in Q3 2021 and bottomed at 3.2% in Q1 2025.
  • The 5-year median for FCF Margin is 32.11% (2022), against an average of 29.61%.
  • The largest annual shift saw FCF Margin plummeted -3085bps in 2022 before it skyrocketed 2887bps in 2024.
  • A 5-year view of FCF Margin shows it stood at 49.95% in 2021, then tumbled by -35bps to 32.37% in 2022, then crashed by -87bps to 4.08% in 2023, then soared by 707bps to 32.95% in 2024, then crashed by -42bps to 19.0% in 2025.
  • Per Business Quant, the three most recent readings for CORT's FCF Margin are 19.0% (Q4 2025), 26.24% (Q3 2025), and 22.57% (Q2 2025).